In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes

Journal of Controlled Release

Volumn 172, Issue 2, 2013, Pages 426-435

  Zheng, Yiran ^a,b   Stephan, Matthias T ^a,b   Gai, S Annie ^a,b   Abraham, Wuhbet ^b   Shearer, Adrianne ^a   Irvine, Darrell J ^a,b,c,d  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD UNIVERSITY   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Adoptive cell therapy; Cancer immunotherapy; Immunoliposomes; Interleukin 2 (IL 2); Melanoma; Targeted delivery

Indexed keywords

CANCER IMMUNOTHERAPY; CELL THERAPY; IMMUNOLIPOSOMES; INTERLEUKIN-2; MELANOMA; TARGETED DELIVERY;

ANTIBODIES; CELL MEMBRANES; CELL PROLIFERATION; CHEMOTHERAPY; DISEASES; LIGANDS; LIPOSOMES; PATIENT TREATMENT; T-CELLS; TUMORS;

CYTOLOGY;

CYTOKINE; FC RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 FC RECEPTOR; LIPOSOME; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE ANTIGEN; THY 1.1 ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SYNTHESIS; FEASIBILITY STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ADOPTIVE CELL THERAPY; CANCER IMMUNOTHERAPY; IMMUNOLIPOSOMES; INTERLEUKIN-2 (IL-2); MELANOMA; TARGETED DELIVERY;

ANIMALS; CELL PROLIFERATION; CYTOKINES; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LIPOSOMES; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES;

EID: 84887121506     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.05.037     Document Type: Article

References (32)

1. I. Mellman, G. Coukos, and G. Dranoff Cancer immunotherapy comes of age Nature 480 2011 480 489
2. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins, P.D. Leming, D.R. Spigel, S.J. Antonia, L. Horn, C.G. Drake, D.M. Pardoll, L. Chen, W.H. Sharfman, R.A. Anders, J.M. Taube, T.L. McMiller, H. Xu, A.J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G.D. Kollia, A. Gupta, J.M. Wigginton, and M. Sznol Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366 2012 2443 2454
3. M. Kalos, B.L. Levine, D.L. Porter, S. Katz, S.A. Grupp, A. Bagg, and C.H. June T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci. Transl. Med. 3 2011 95ra73
4. S.A. Rosenberg, J.C. Yang, R.M. Sherry, U.S. Kammula, M.S. Hughes, G.Q. Phan, D.E. Citrin, N.P. Restifo, P.F. Robbins, J.R. Wunderlich, K.E. Morton, C.M. Laurencot, S.M. Steinberg, D.E. White, and M.E. Dudley Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clin. Cancer Res. 17 2011 4550 4557
5. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells Proc. Natl. Acad. Sci. U. S. A. 99 2002 16168 16173 (Pubitemid 35462767)
6. R.A. Morgan, M.E. Dudley, J.R. Wunderlich, M.S. Hughes, J.C. Yang, R.M. Sherry, R.E. Royal, S.L. Topalian, U.S. Kammula, N.P. Restifo, Z. Zheng, A. Nahvi, C.R. de Vries, L.J. Rogers-Freezer, S.A. Mavroukakis, and S.A. Rosenberg Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 2006 126 129 (Pubitemid 44547756)
7. N.P. Restifo, M.E. Dudley, and S.A. Rosenberg Adoptive immunotherapy for cancer: harnessing the T cell response Nat. Rev. Immunol. 12 2012 269 281
8. M.J. Besser, R. Shapira-Frommer, A.J. Treves, D. Zippel, O. Itzhaki, L. Hershkovitz, D. Levy, A. Kubi, E. Hovav, N. Chermoshniuk, B. Shalmon, I. Hardan, R. Catane, G. Markel, S. Apter, A. Ben-Nun, I. Kuchuk, A. Shimoni, A. Nagler, and J. Schachter Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients Clin. Cancer Res. 16 2010 2646 2655
9. + T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host J. Am. Coll. Surg. 214 2012 700 707 (discussion 707-708)
10. + cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy J. Immunother. 33 2010 547 556
11. H. Kobayashi, Y. Tanaka, J. Yagi, N. Minato, and K. Tanabe Phase I/II study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma Cancer Immunol. Immunother. 60 2011 1075 1084
12. J.C. Markley, and M. Sadelain IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice Blood 115 2010 3508 3519
13. + T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts Cancer Res. 70 2010 6725 6734
14. + T-cell clone following retroviral transduction with the IL-15 gene Blood 109 2007 5168 5177 (Pubitemid 46890533)
15. M.T. Stephan, J.J. Moon, S.H. Um, A. Bershteyn, and D.J. Irvine Therapeutic cell engineering with surface-conjugated synthetic nanoparticles Nat. Med. 16 2010 1035 1041
16. M.T. Stephan, S.B. Stephan, P. Bak, J. Chen, and D.J. Irvine Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles Biomaterials 33 2012 5776 5787
17. T.M. Fahmy, J.P. Schneck, and W.M. Saltzman A nanoscopic multivalent antigen-presenting carrier for sensitive detection and drug delivery to T cells Nanomedicine 3 2007 75 85 (Pubitemid 46428189)
18. S. Tsai, A. Shameli, J. Yamanouchi, X. Clemente-Casares, J. Wang, P. Serra, Y. Yang, Z. Medarova, A. Moore, and P. Santamaria Reversal of autoimmunity by boosting memory-like autoregulatory T cells Immunity 32 2010 568 580
19. X. Clemente-Casares, S. Tsai, Y. Yang, and P. Santamaria Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach? J. Mol. Med. 89 2011 733 742
20. X. Wang, W.C. Chang, C.W. Wong, D. Colcher, M. Sherman, J.R. Ostberg, S.J. Forman, S.R. Riddell, and M.C. Jensen A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells Blood 118 2011 1255 1263
21. M. Kalos Biomarkers in T cell therapy clinical trials J. Transl. Med. 9 2011 138
22. Y. Minami, T. Kono, T. Miyazaki, and T. Taniguchi The IL-2 receptor complex: its structure, function, and target genes Annu. Rev. Immunol. 11 1993 245 268
23. B. Kwong, S.A. Gai, J. Elkhader, K.D. Wittrup, and D.J. Irvine Localized immunotherapy via liposome-anchored anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity Cancer Res. 73 2013 1547 1558
24. L. Baudino, Y. Shinohara, F. Nimmerjahn, J. Furukawa, M. Nakata, E. Martinez-Soria, F. Petry, J.V. Ravetch, S. Nishimura, and S. Izui Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions J. Immunol. 181 2008 6664 6669
25. + T cells J. Exp. Med. 198 2003 569 580 (Pubitemid 37040391)
26. J.W. Lowenthal, P. Corthesy, C. Tougne, R. Lees, H.R. MacDonald, and M. Nabholz High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61 J. Immunol. 135 1985 3988 3994 (Pubitemid 16250380)
27. J.W. Lowenthal, R.H. Zubler, M. Nabholz, and H.R. MacDonald Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes Nature 315 1985 669 672 (Pubitemid 15232880)
28. B. Kwong Liposome-anchored local delivery of immunomodulatory agents for tumor therapy Biological Engineering 2012 Massachusetts Institute of Technology (http://hdl.handle.net/1721.1/76115)
29. R.F. Murphy, S. Powers, and C.R. Cantor Endosome pH measured in single cells by dual fluorescence flow cytometry: rapid acidification of insulin to pH 6 J. Cell Biol. 98 1984 1757 1762 (Pubitemid 14102601)
30. C.A. Klebanoff, H.T. Khong, P.A. Antony, D.C. Palmer, and N.P. Restifo Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy Trends Immunol. 26 2005 111 117
31. M.E. Dudley, J.R. Wunderlich, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R.M. Sherry, F.M. Marincola, S.F. Leitman, C.A. Seipp, L. Rogers-Freezer, K.E. Morton, A. Nahvi, S.A. Mavroukakis, D.E. White, and S.A. Rosenberg A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma J. Immunother. 25 2002 243 251 (Pubitemid 34533314)
32. M.W. Konrad, G. Hemstreet, E.M. Hersh, P.W. Mansell, R. Mertelsmann, J.E. Kolitz, and E.C. Bradley Pharmacokinetics of recombinant interleukin 2 in humans Cancer Res. 50 1990 2009 2017 (Pubitemid 20115067)